Latest AI and machine learning research in alzheimer's disease for healthcare professionals.
Here the current and emerging roles of brain positron emission tomography (PET) in Alzheimer's disease (AD) in the era of anti-amyloid-β antibody therapy, with a focus on clinical applications, methodological considerations, and future perspectives were reviewed. A narrative review of the literature on PET imaging in AD, including FDG-PET, amyloid PET, and tau PET, was conducted with particular em...
Early diagnosis of Alzheimer's disease (AD) is crucial for timely intervention but remains challenging due to subtle and heterogeneous brain alterations, particularly in the mild cognitive impairment (MCI) stage. To address this issue, we propose a pathology-aware Adaptive Neighborhood Aggregation Graph Neural Network (ANA-GNN) to model the brain as a dynamic and task-driven graph for multimodal A...
Some schizophrenia patients share characteristics with behavioral variant frontotemporal dementia (bvFTD) including gray matter volume (GMV) similarit...
Alzheimer's disease (AD) and Huntington's disease (HD) share neuroinflammatory mechanisms, yet their specific immune microenvironments remain poorly u...
The concept of brain reserve offers a framework for understanding the mechanisms of cognitive resilience in later life. This study investigated whethe...
BACKGROUND AND OBJECTIVES: Cerebral small vessel disease (SVD) is the most common vascular contributor to dementia. SVD markers often coexist, contrib...
Cardiac amyloidosis (CA), a fatal and progressive cardiomyopathy is characterized by amyloid deposition within the myocardium. The main forms of CA in...
BACKGROUND: MRI is important for cardiac disease evaluation, but accurate diagnosis remains challenging in less experienced centers. Although large la...
BackgroundEarly diagnosis of dementia is essential for enabling timely interventions that may slow disease progression, improve patient outcomes, and ...
Atomic force microscopy (AFM) enables label-free nanoscale imaging and nanomechanical profiling but remains constrained by low throughput, operator de...
The specific neuroanatomy of mild cognitive impairment (MCI) is obscured by its clinical heterogeneity and confounding effects from normative variatio...
The drug development for central nervous system (CNS) disorders, particularly neurodegenerative diseases, such as Alzheimer's disease, Parkinson's dis...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and substantial brain atrophy. Early and accur...
Extensive studies have shown that cerebrovascular dysfunction is a critical factor in the onset and progression of Alzheimer's disease (AD). Neurovasc...
Brain-machine interfaces (BMIs), which serve as revolutionary tools for neural recording, modulation, and rehabilitation, are highly dependent on the ...
BACKGROUND: With the growing aging population, technology that supports independent living is increasingly important. Web search systems are well esta...
Exhaled volatile organic compounds (VOCs) have been investigated in some diseases, including cognitive impairment, in pilot studies. The present study...
BACKGROUND: Effective screening and cohort enrichment remain major challenges in clinical trials for Alzheimer's disease (AD), where traditional diagn...
BACKGROUND: Treatment-as-usual (TAU) conditions are intended to reflect the support typically received in routine treatment settings. For digital ment...